Paediatric ulcerative colitis

Active Ingredient: Adalimumab

Indication for Adalimumab

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)
Therapeutic intent: Curative procedure

Adalimumab is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.

For this indication, competent medicine agencies globally authorize below treatments:

80 or 160 mg at Week 0 and 40 or 80 mg at Week 2 and every other week based on body weight

For:

Dosage regimens

Regimen A, in case that patient age in years is ≥ 6 and patient weight is < 40 kg

Subcutaneous, 80 milligrams adalimumab, one dose, over the duration of 2 weeks. Afterwards, subcutaneous, 40 milligrams adalimumab, once every 2 weeks.

Regimen B, in case that patient age in years is ≥ 6 and patient weight is ≥ 40 kg

Subcutaneous, 160 milligrams adalimumab, one dose, over the duration of 2 weeks. Afterwards, subcutaneous, 80 milligrams adalimumab, once every 2 weeks.

Detailed description

The recommended dose of adalimumab for patients from 6 to 17 years of age with ulcerative colitis is based on body weight. Adalimumab is administered via subcutaneous injection.

Adalimumab Dose for Paediatric Patients with Ulcerative Colitis:

Patient WeightInduction DoseMaintenance Dose
Starting at Week 4*
<40 kg• 80 mg at Week 0 (given as two 40
mg injections in one day) and
• 40 mg at Week 2 (given as one 40
mg injection)
• 40 mg every other week
≥40 kg• 160 mg at Week 0 (given as four
40 mg injections in one day or
two 40 mg injections per day for
two consecutive days) and
• 80 mg at Week 2 (given as two 40
mg injections in one day)
• 80 mg every other week

* Paediatric patients who turn 18 years of age while on adalimumab should continue their prescribed maintenance dose.

Continued therapy beyond 8 weeks should be carefully considered in patients not showing signs of response within this time period.

There is no relevant use of adalimumab in children aged less than 6 years in this indication.

Active ingredient

Adalimumab

Adalimumab binds specifically to TNF and neutralizes the biological function of TNF by blocking its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also modulates biological responses that are induced or regulated by TNF, including changes in the levels of adhesion molecules responsible for leukocyte migration (ELAM-1, VCAM-1, and ICAM-1 with an IC50 of 0.1-0.2 nM).

Read more about Adalimumab

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.